NICE In CDF Rethink Says OK To Bosulif For General NHS Use In CML
Pfizer Inc.'s Bosulif (bosutinib) will now become generally available on the UK's publicly-funded NHS for use in certain types of chronic myeloid leukemia after NICE reassessed the tyrosine kinase inhibitor in light of new data and a bigger pro-offered price discount from its manufacturer. The drug was previously only available through the country's controversial Cancer Drugs Fund (CDF).
You may also be interested in...
England's new Cancer Drugs Fund is to go ahead with little change to proposals that have proved unpopular with companies. The Association of the British Pharmaceutical Industry says the new system will take patients and companies back to the situation in 2010 before the CDF was set up and that two thirds of CDF-financed drugs will be unavailable by the end of the year. Eisai has slammed the new fund, warning that drugs approved after the CDF closed its doors to funding new products will float in limbo with no clear means of getting to patients.
NICE, the health technology appraisal institute for England and Wales, has joined the growing swell of European HTAs rejecting Pfizer's chronic myeloid leukemia (CML) drug Bosulif (bosutinib).
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.